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Abstract
Purpose To investigate the mortality in both in- and outpatients with personality disorders (PD), and to explore the associa-
tion between mortality and comorbid substance use disorder (SUD) or severe mental illness (SMI).
Methods All residents admitted to Norwegian in- and outpatient specialist health care services during 2009–2015 with a PD 
diagnosis were included. Standardized mortality ratios (SMRs) with 95% confidence intervals (CI) were estimated in patients 
with PD only and in patients with PD and comorbid SMI or SUD. Cox proportional hazards models were used to estimate 
adjusted hazard ratios (HRs) with 95% CIs in patients with PD and comorbid SMI or SUD compared to patients with PD only.
Results Mortality was increased in both in- and outpatients with PD. The overall SMR was 3.8 (95% CI 3.6–4.0). The highest 
SMR was estimated for unnatural causes of death (11.0, 95% CI 10.0–12.0), but increased also for natural causes of death 
(2.2, 95% CI 2.0–2.5). Comorbidity was associated with higher SMRs, particularly due to poisoning and suicide. Patients 
with comorbid PD & SUD had almost four times higher all-cause mortality HR than patients with PD only; young women 
had the highest HR.
Conclusion The SMR was high in both in- and outpatients with PD, and particularly high in patients with comorbid PD & 
SUD. Young female patients with PD & SUD were at highest risk. The higher mortality in patients with PD cannot, however, 
fully be accounted for by comorbidity.
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Introduction
Personality disorders (PDs) are characterized by personal-
ity traits causing suffering, reduced quality of life and often 
reduced ability to maintain interpersonal relationships [1, 
2]. PDs are etiologically complex diagnostic categories with 
a high prevalence of comorbidity with other mental disor-
ders in both population-based [2–6] and clinical samples 
[7]. A meta-analysis from 2020 including studies based on 
both DSM and ICD criteria shows the worldwide pooled 
prevalence of PDs in the general population to be 7.8%, and 
higher in high-income countries (9.6%)[8]. Patients with 
PDs are in frequent and in some cases long-term contact 
with health care services due to their mental illness. Studies 
have demonstrated that 24%of patients in primary care meet 
criteria for a PD diagnosis [9], and 50% of all patients in 
psychiatric outpatient care [10]. The prevalence rate among 
psychiatric inpatients is shown to be considerably lower; 
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about 15% for PD as primary or secondary diagnosis [11]. 
The prevalence is higher for women than for men in spe-
cialist health care services, while the opposite is the case in 
community settings [2, 10, 12].
Approximately one in five people with bipolar disorder is 
also diagnosed with borderline or emotionally unstable PD 
[13], affective and anxiety disorders are strongly associated 
with schizotypal PD [14], and the prevalence rate of PDs in 
individuals at high risk for psychosis has been found to be 
as high as 39% [15]. There is also a well-known relationship 
between PDs and substance use disorder (SUD) [16–24]. A 
clinical study from Denmark found comorbid SUD in 39% 
of patients with PDs [16], and a systematic review from 
2000 estimates that 38–57% of patients with borderline PD 
have at least one SUD diagnosis [24]. The co-occurrence of 
PDs with other mental disorders or SUD in the same individ-
ual can be explained by a number of factors [25] including 
common genetic vulnerability [26–29], shared environmen-
tal factors such as trauma and abuse exposure [20, 30, 31], 
externalizing/internalizing dimensions, and common liabil-
ity factors in different disorders [32–35]. In a population 
based, Norwegian twin study, genetic risks for borderline 
and antisocial PD explained 32–60% of the total variance in 
cannabis use and cannabis use disorder [26, 27]. Genetic risk 
for dependent PD explained 11% of the variance, whereas 
genetic risk for avoidant PDs explained 16% of the variance.
In a study by Nordentoft and coworkers, the highest 
observed/expected mortality ratios (standardized mortality 
ratios, SMRs) were found for SUD and PD [36]. Other stud-
ies show a similar pattern [37–42], also in patients receiving 
only outpatient care [43]. The increased mortality may to a 
large degree be explained by a higher prevalence of unnatu-
ral causes of death such as suicide and accidents, especially 
in borderline PD [41, 44–48], but also a higher prevalence 
of natural causes of death [12, 39, 42, 43, 49, 50].
Even though the co-occurrence of PDs and other men-
tal disorders is shown to be associated with the course and 
treatment outcome negatively [1, 2, 4], very few studies 
have addressed the association between psychiatric comor-
bidity and mortality in individuals with PD. Björkenstam 
et al. [42] reported SMRs in patients with PD to be 3.3 for 
women and 2.4 for men, whereas SMR in patients who had 
also been admitted with other psychiatric or somatic dis-
eases was 6.5 for women and 5.7 for men. In 2018, Kuo 
and coworkers were the first to publish data on the asso-
ciation between comorbid SUD and other axis I psychiatric 
disorders on SMRs among patients with a PD admitted to 
hospital [12]. SMRs for all-cause mortality of PD only, PD 
with non-SUD mental disorders and PD with SUD were 4.5, 
7.4, and 16.0, respectively. Kjær and coworkers found SMR 
of patients with borderline PD to be 8.3 [47], and that more 
than three yearly hospital admissions or a comorbid SUD 
were factors significantly associated with higher mortality. 
To our knowledge, no previous study has investigated the 
association between comorbid SUD or SMI and mortality in 
patients with PDs admitted to outpatient services.
The aims of the present study were to use prospective 
data from nationwide health registries to estimate the mor-
tality (all-cause mortality as well as mortality due to natural 
and unnatural deaths) in both in- and outpatients with PD 
compared with the general population, and to explore the 
impact of comorbid SUD or SMI (defined as schizophrenia, 
bipolar disorder or major depression), or a combination of 
these disorders, on mortality in patients with PDs.
Materials and methods
Study population
All patients aged 20–79 years who received a diagnosis of 
PD in the Norwegian Patient Registry (NPR) between 2009 
and 2015 were included. NPR contains information about 
all in- and outpatient treatment in somatic and psychiatric 
specialized health care in Norway (i.e., state-owned hos-
pitals and outpatient clinics, government-funded substance 
use treatment facilities, and private health clinics with gov-
ernmental reimbursement). The NPR has almost complete 
coverage from 2009. Patients were excluded if a valid social 
security number was missing (n = 2186), a diagnosis of intel-
lectual disability (n = 365) or inconsistent data regarding 
age, gender or emigration date (n = 27) were recorded.
Diagnostic categories
Diagnostic codes in the NPR follow the International Clas-
sification of Diseases and Related Health Problems, 10th 
Revision (ICD-10) [51]. Patients were included in the PD 
group if they had at least one ICD-10 code F60 recorded in 
the NPR during 2009–2015. Patients identified exclusively 
in somatic care constituted 2% of the PD group.
Comorbid SMI was considered present if a diagnosis 
of schizophrenia-related disorder (codes F20-F29), bipo-
lar disorder (codes F30-F31) or major depression (codes 
F32.2-F32.3, F33.2-F33.3) was recorded from 2009 to 2015. 
Comorbid SUD was considered present if a diagnosis of 
mental and behavioral disorders due to use of psychoac-
tive substances (F10-F19, excluding tobacco (F17)), or a 
somatic diagnosis strongly indicating alcohol abuse (codes 
K70, E52, E24.4, G31.2, G62.1, G72.1, I42.6, K29.2, K86.0, 
O35.4, Y57.3, Z50.2, Z50.3, Z71.4, and Z72.1) was recorded 
between 2009 and 2015. Patients identified by somatic diag-
noses only constituted 0.5% of the SUD group. In addition, 
we included in the PD & SUD group 393 PD patients with 
repeated episodes in drug treatment facilities without any 
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registered diagnosis of SUD. This group was considered to 
be patients with unknown SUD.
Information on causes of death
The unique social security number assigned to all Norwe-
gian residents was used to link information from the NPR 
to two other nationwide population-based registries; the 
National Population Registry and the Cause of Death Regis-
try. The National Population Registry provided information 
on the year of birth, emigration and date of death. The Cause 
of Death Registry, which includes information about 98% of 
all deaths in Norway [52], provided data on the underlying 
cause of death. Causes of death were based on death certifi-
cates coded by the physician who examined the deceased. 
Overall, approximately 8% of cases in the Cause of Death 
Registry were supplemented by autopsy data. Causes of 
death were coded according to ICD-10, and divided into 
natural causes (A00-R99), unnatural causes (V01-Y98), and 
missing cause of death. Natural causes of death were further 
divided into cancer (C00-C97), cardiovascular (I00-I99), 
respiratory (J00-J99), mental and behavioral (F00-F99), 
and other natural causes. Unnatural causes of death were 
divided into poisoning (X40-X49), suicide (X60-X84 and 
Y87.0), and other unnatural causes. The reference popula-
tion included all residents in Norway who for each of the 
years 2009 to 2015 were between 20 and 79 years of age by 
the end of the year. Annual number of deaths in sex-strati-
fied five-year age groups for the reference population were 
obtained from the Norwegian Institute of Public Health [53], 
and annual population figures in the age groups 20–79 in the 
years 2009–2015 were obtained from Statistics Norway [54].
Statistical analysis
To study the association between psychiatric comorbidity on 
relative mortality, we split the PD group into three groups; 
PD only (e.g., no diagnosis of SMI or SUD in the period), 
PD & SMI (without SUD), and PD & SUD (with or without 
SMI). We merged the two groups of PD & SUD with and 
without SMI in the analyses, but sensitivity analyses were 
performed. We calculated the relative mortality compared 
to the general population (SMRs) with corresponding 95% 
confidence intervals (CIs) for all patients with PD, patients 
with PD only, PD & SMI (but not SUD), and PD & SUD 
(with and without SMI). To examine the impact of diagnos-
tic instability or uncertainty, we performed sensitivity analy-
ses including (i) only individuals with a single PD diagnosis 
and (ii) only individuals with repeated PD diagnosis.
The SMR is computed as the observed number of deaths 
divided by the expected number of deaths, and shows the 
relative mortality of the patient group compared to that of 
the general population of similar age and sex. The expected 
number of deaths was calculated as the total number of 
person-years at risk in each sex-, age group-, and calendar 
year band, multiplied by the corresponding age- (5-year age 
groups), sex-, and calendar-year specific (2009–2015) death 
rate in the general population. Age was defined as attained 
age at the end of each calendar year. Person-years at risk 
contributed by persons who moved from one age band to 
the next during follow-up was assigned to the respective 
sex-, age group-, and calendar year bands, using the “lexis” 
method [55]. The study cohort was followed from the date 
of their first consultation or admission with a PD diagno-
sis in the period 2009–2015. Patients already hospitalized 
before January 1, 2009 (n = 312) were followed from this 
date. Follow-up ended on December 31, 2015, on the date of 
emigration, on December 31 in the year of the 79th birthday, 
or on the date of death, whichever came first. We present 
sex-specific SMRs for all PD patients according to cause of 
death, followed by SMRs for PD only, PD & SMI and PD 
& SUD, overall and stratified by sex and in- or outpatient 
status.
To compare mortality within the PD group, we used Cox 
proportional hazards models with attained age as the under-
lying time scale to estimate adjusted hazard ratios (HRs) 
with 95% CIs in patients with PD and comorbid SMI or 
SUD compared to patients with PD only. In patients with PD 
& SUD, the association was clearly attenuated by attained 
age (stronger relationship in younger patients). Thus, we 
also present analyses stratified according to age group 
(age at start of follow-up 15–34 years, 35–49 years and 
50–79 years). The analyses were performed using SAS sta-
tistical software, version 9.4 (SAS Institute Inc., Cary, N.C.).
Results
Characteristics of the study populations
We identified 32,885 adult patients with PD (60% females) 
(Table 1). A majority of the patients (70%) were treated as 
outpatients only; 86% in PD only, 59% in PD & SMI, and 
48% in PD & SUD, respectively. The most common PDs 
were F60.3 Emotionally unstable PD (30.3%), F60.6 Anx-
ious (avoidant) PD (27.9%), and F60.9 Unspecified PD. The 
patients were followed for a mean of 4.0 years (SD 2.3). 
Women were overrepresented in the PD only group (63%) 
and in the PD & SMI group (66%). Mean age at entry was 
37.4 years (SD 12.0) in patients with PD only, 38.8 (SD 
12.5) in patients with PD & SMI, and 36.2 (SD 11.7) in 
patients with PD & SUD.
Rates of psychiatric comorbidity were high. With cat-
egories not mutually exclusive, the most common comorbid 
diagnosis among those with PD & SMI was major depres-
sion (47%), whereas 42% had a registered bipolar disorder 
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diagnosis and 26% a schizophrenia-related diagnosis. In 
the PD & SUD group, the majority of the patients (55%) 
had registered mixed drugs use disorder (ICD-10 code F19 
Mental and behavioral disorders due to multiple drug use 
and use of other psychoactive substances), or a combination 
of other F1-diagnoses. 24% had alcohol use disorder only, 
12% had hard drug use only (ICD-10 codes F11, F13, F16, 
and Z50.3), 6% had cannabis use disorder only, and 4% had 
unknown drug use disorder.
All‑cause and cause‑specific mortality
Of the 32,885 patients included, 890 died during the follow-
up, 434 women (2.2%) and 456 men (3.5%). Mortality due 
to both natural and unnatural deaths was elevated in both 
PD only, PD & SMI, and PD & SUD, compared to what was 
expected in the general population. As shown in Table 2, 
comorbidity was generally related to higher SMRs. There 
were overall significantly higher SMRs in patient with PD & 
SMI (but no SUD) compared to patients with PD only, and 
significantly higher SMRs in patients with PD & SUD (with 
and without SMI) compared to patients with PD & SMI 
without SUD. The largest association between comorbidity 
and SMRs was observed for unnatural causes in both men 
and women, as displayed in Fig. 1. Comorbidity was associ-
ated with particularly high SMRs due to unnatural causes, 
3.8 (95% CI 3.0–4.7) in PD only, 11.1 (95% CI 8.9–13.8) in 
PD & SMI, and 22.5 (95% CI 20.1–25.3) in PD & SUD. In 
the PD & SUD group, SMR was extremely high for poison-
ing (36.7, 95% CI 30.9–43.7) but also for suicide (23.9, 95% 
CI 20.1–28.5). The mortality in patients with PD & SUD 
was higher also due to natural causes of death; death because 
of respiratory diseases having a ninefold and cardiovascular 
death a twofold increase compared to the general population. 
Table 1  Demographic and 
clinical characteristics of the 
study population
PD personality disorder, SMI severe mental illness, SUD substance use disorder, n number of patients, SD 
standard deviation
a Includes patients with PD & SUD, with and without SMI
b ICD-10 codes F10, K70, E52, E24.4, G31.2, G62.1, G72.1, I42.6, K29.2, K86.0, O35.4, O35.5, Y57.3, 
Z50.2, Z71.4, and Z72.1
c ICD-10 codes F11, F13, F14, F15, F16, and Z50.3
d ICD-10 code F19 or combinations of other F1-diagnoses
e Includes persons with repeated episodes at substance use treatment facilities, but no diagnosis of SUD or 
pathological gambling
All PD patients PD only PD & SMI PD &  SUDa
Patients, n 32,885 17,432 833 9620
Women, n (%) 19,747 (60.0) 11,000 (63.1) 3830 (65.7) 4,917 (51.1)
Age at entry, mean (SD) 37.3 (12.0) 37.4 (12.0) 38.8 (12.5) 36.2 (11.7)
Women 36.8 (12.3) 36.8 (12.8) 38.2 (12.8) 35.8 (12.3)
Men 38.0 (11.6) 38.5 (12.0) 40.0 (12.0) 36.6 (11.0)
Treatment level, n (%)
Inpatient treatment 9,858 (30.0) 2,481 (14.2) 2,389 (41.0) 4,988 (51.9)
Outpatient treatment only 23,027 (70.0) 14,951 (85.8) 3,444 (59.0) 4,632 (48.1)
SUD, n (%)
Alcohol use disorder  onlyb 2298 (7.0) 0 0 2298 (23.9)
Cannabis use disorder only 555 (1.7) 0 0 555 (5.8)
Hard drug use disorders  onlyc 1121 (3.4) 0 0 1121 (11.7)
Mixed drug use  disorderd 5253 (16.0) 0 0 5253 (54.6)
Unknown drug use  disordere 393 (1.2) 0 0 393 (4.1)
Severe mental disorders, n (%)
Schizophrenia 2860 (8.7) 0 1520 (26.1) 1340 (13.9)
Bipolar disorder 3956 (12.0) 0 2451 (42.0) 1505 (15.6)
Major depression 4261 (13.0) 0 2717 (46.6) 1544 (16.0)
Deaths 890 (2.7) 248 (1.4) 181 (3.1) 461 (4.8)
Women, n (%) 434 (1.3) 138 (0.8) 103 (1.8) 193 (2.0)
Total follow-up (person-years) 131,042 68,399 24,266 38,377
Follow up per patient, person-
years, mean (SD)
4.0 (2.3) 3.9 (2.3) 4.2 (2.2) 4.0 (2.2)
Deaths per 1000 person-years 6.8 3.6 7.5 12.0
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For natural causes of death in patients with comorbid PD & 
SMI, SMR was also highest for respiratory diseases, albeit 
substantially lower than in patients with PD & SUD. Mor-
tality was higher for natural and unnatural causes of death 
in both inpatients and patients treated solely in outpatient 
settings, the only exception being natural causes of death 
in patients with PD only treated as outpatients only (SMR 
1.0, 95% CI 0.8–1.3). In outpatients, all-cause mortality was 
doubled compared to the general population, with signifi-
cantly higher SMRs both in PD only (1.3, 95% CI 1.1–1.5), 
PD & SMI (2.3, 95% CI 1.8–3.0), and PD & SUD (5.3, 
95% CI 4.5–6.3). For patients admitted to hospital, SMRs 
were markedly higher (7.0, 95% CI 6.5–7.6) than in patients 
treated solely in outpatient clinics.
Comparative analyses within the PD group showed that 
mortality was markedly higher in all age groups for both 
men and women with comorbid SMI and SUD, compared to 
those with PD only (Table 3). The HR was particularly high 
in those with PD & SUD, the most vulnerable groups being 
women aged 20–34 years (HR = 7.2, 95% CI 4.5–11.7) and 
men aged 35–49 (HR = 5.7, 95% CI 3.8–8.8).
Sensitivity analyses with three different comorbidity 
groups showed coinciding SMRs between the two groups 
PD & SUD (but no SMI), and PD & SUD & SMI (Table S1). 
Sensitivity analyses of individuals with a repeated PD diag-
nosis showed somewhat lower SMRs due to both natural 
and unnatural causes of death, in both the PD only and the 
comorbid groups. The pattern of higher SMRs in the comor-
bid groups remained, however, consistent (Table S2).
Discussion
Our study shows that patients with PD have almost four 
times higher mortality than the general population, with 
highest SMRs for poisoning and suicide. Relative mortal-
ity was substantially higher in patients diagnosed with SMI 
and/or SUD in addition to PD. The mortality in patients with 
PD and comorbid SUD compared to the mortality in the 
general population was extremely high for unnatural causes 
of deaths. These patients had an almost four times higher 
all-cause mortality HR than patients with PD only. Poison-
ing was the cause of death with the overall highest SMRs 
in patients with PD & SUD group, but the increased SMRs 
were also present in natural causes of death. The mortality 
Table 2  All-cause and cause-specific standardized mortality ratios for patients with a personality disorder diagnosis with and without psychiatric 
comorbidity
CI confidence interval, Obs number of deaths, PD personality disorder, SMI severe mental illness, SMR standardized mortality ratio, SUD sub-
stance use disorder
a Includes patients with PD & SUD, with and without SMI
All PD patients PD only PD & SMI PD &  SUDa
Deaths SMR 95% CI Deaths SMR 95% CI Deaths SMR 95% CI Deaths SMR 95% CI
All causes 890 3.8 (3.6–4.0) 248 2.0 (1.7–2.2) 181 3.7 (3.2–4.3) 461 7.6 (6.9–8.3)
Natural causes 416 2.2 (2.0–2.5) 161 1.6 (1.4–1.9) 94 2.4 (1.9–2.9) 161 3.5 (3.0–4.1)
  Cancer 125 1.4 (1.2–1.6) 63 1.3 (1.0–1.6) 29 1.5 (1.0–2.1) 33 1.5 (1.1–2.1)
 Cardiovascular 92 2.4 (2.0–2.9) 39 1.9 (1.4–2.6) 27 3.3 (2.2–4.8) 26 2.7 (1.9–4.0)
 Respiratory 47 4.0 (3.0–5.3) 13 2.0 (1.2–3.5) 10 3.6 (1.9–6.6) 24 9.3 (6.2–13.8)
 Mental disorders 32 7.9 (5.6–11.2) 5 2.3 (1.0–5.6) 3 3.3 (1.1–10.3) 24 24.8 (16.6–37.0)
 Other natural 120 3.0 (2.5–3.6) 41 1.9 (1.4–2.6) 25 3.0 (2.0–4.4) 54 5.2 (4.0–6.8)
Unnatural causes 450 11.0 (10.0–12.0) 79 3.8 (3.0–4.7) 81 11.1 (8.9–13.8) 290 22.5 (20.1–25.3)
 Poisoning 151 14.0 (11.9–16.4) 11 2.0 (1.1–3.6) 12 6.4 (3.6–11.2) 128 36.7 (30.9–43.7)
 Suicide 251 15.0 (13.2–17.0) 61 7.2 (5.6–9.2) 64 21.6 (16.9–27.6) 126 23.9 (20.1–28.5)
 Other unnatural 48 3.6 (2.7–4.8) 7 1.0 (0.5–2.2) 5 2.0 (0.9–4.9) 36 8.8 (6.3–12.2)
Missing 24 3.9 (2.6–5.8) 8 2.4 (1.2–4.9) 6 4.9 (2.2–11.0) 10 6.0 (3.2–11.2)
Inpatients
 All causes 558 7.0 (6.5–7.6) 114 5.3 (4.4–6.4) 124 5.2 (4.3–6.2) 320 9.4 (8.4–10.4)
 Natural causes 245 3.8 (3.4–4.3) 76 4.3 (3.3–5.3) 62 3.1 (2.4–4.0) 107 4.1 (3.4–4.9)
 Unnatural causes 299 23.1 (20.6–25.9) 36 12.4 (8.8–17.2) 59 19.1 (14.5–24.4) 204 29.4 (25.5–33.5)
Outpatients only
 All causes 332 2.1 (1.9–2.4) 134 1.3 (1.1–1.5) 57 2.3 (1.8–3.0) 141 5.3 (4.5–6.3)
  Natural causes 171 1.4 (1.2–1.6) 85 1.0 (0.8–1.3) 32 1.6 (1.1–2.3) 54 2.8 (2.1–3.6)
  Unnatural causes 151 5.4 (4.6–6.3) 43 2.4 (1.8–3.2) 22 5.2 (3.4–7.9) 86 14.5 (11.8–17.9)
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was highest in the inpatient group. For patients with comor-
bid PD & SMI, the HR was doubled.
The conceptualization of PD in ICD-10 is broader than 
in the DSM-IV and DSM-5 [4, 56], which may affect the 
comparison between studies, but still our findings on over-
all increased mortality is in accordance with findings from 
previous studies [12, 38–40, 42, 43, 57–60]. In our cohort, 
F60.3 Emotionally unstable PD was the most frequent 
subtype (30.3%). This is in line with Kuo and coworkers, 
where 33.4% had borderline PD [12]. Emotionally unstable 
PD (ICD-10) or borderline PD (DSM 5) are, however, often 
more frequent diagnoses in inpatient cohorts, probably due 
to the severe clinical characteristics and increased need for 
hospital care in these patients. A possible explanation of 
the distribution in our study may hence be the inclusion of 
outpatients, as well as the inclusion of patients treated in 
somatic health care with a PD diagnosis.
Even so, we find that all-cause, natural, and unnatural 
SMRs for inpatients in our study are in line with other 
recent studies [12, 42], but with slightly higher SMR for 
unnatural causes (23.1, 95% CI 20.6–25.9) than Kuo and 
coworkers (15.5; 12.3–18.7) [12]. For patients with outpa-
tient care only, we found somewhat lower all-cause SMR 
(2.1; 1.9–2.4) than Björkenstam and coworkers [43], where 
total SMRs were 3.7 (3.3–4.1) in women and 3.8 (3.4–4.2) 
in men.
Our finding of a very high SMRs among patients with 
comorbid PD & SUD is in line with other studies showing 
that alcohol and drug use significantly increases mortality in 
individuals with PD [12, 47, 50, 61]. Crump and coworkers 
demonstrated that mortality due to accidents, which included 
death by poisoning, was higher than suicide mortality in all 
mental disorders, with PD at the highest risk with a four-to-
sevenfold increase [46].
The high mortality in individuals with SMI or SUD is 
well known [36, 40, 60, 62]. The reasons for the increased 
mortality for patients when PD is comorbid with SMI or 
SUD are not clear, but severe personality pathology is 
Fig. 1  Sex-specific all-cause and cause-specific standardized mortality ratios with 95% confidence intervals for patients with personality disorder 
with and without psychiatric comorbidity
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characterized by lack of emotional regulation and may, as a 
consequence, lead to aggravation of self-destructive or risk-
taking behavior under the influence of substance use; with 
or without intention [46, 63].
A more fundamental problem of the PD conceptual-
ization is the generally high degree of comorbidity, both 
between different PDs, but also with other mental disorders, 
probably caused by personality disturbances having a more 
dimensional rather than categorical quality. The dimen-
sional classification of PDs in ICD-11 aims at eliminating 
this “artificial comorbidity”, both for research and clinical 
purposes [64]. The pattern of high mortality in the comorbid 
groups in our study may thus reflect a more general symptom 
severity, with personality disturbances in a complex inter-
play with other mental symptoms, rather than a pattern of 
high mortality within distinct categories. It could also be 
that registered comorbidity with SMI represents diagnos-
tic insecurity rather than co-existing fulfilment of separate 
diagnostic criteria.
In contrast to the generally higher SMRs in the comorbid 
groups compared to the PD only group, the SMRs due to 
natural causes of death in inpatients with PD & SMI or PD 
& SUD was, somewhat surprisingly, similar or lower than 
SMR in the PD only group. This finding may simply be a 
chance finding or it may be due to a more extensive follow-
up of somatic conditions in the comorbid groups, or lower 
degree of help-seeking behavior for somatic conditions in 
the PD only group.
Strengths and limitations
The study includes a nationwide, complete data sample from 
both inpatient and outpatient specialized psychiatric and 
somatic health care in a country with publicly funded health 
care services for the entire population, ensuring generaliz-
able estimates of mortality. The validity of clinically based 
registry diagnoses is often questioned, but high agreement in 
Norwegian registry and research based diagnoses of SMI has 
been shown [65] and a recent validity study from the Swed-
ish National Patient Register reports an agreement of 93% 
for PD diagnoses according to ICD-10 criteria, somewhat 
lower for DSM criteria [56]. The validity of data on under-
lying cause of death in the Norwegian CDR is high [66]. In 
the PD & SUD group in our study, “mental disorders” as an 
underlying natural cause of death is, however, used more 
often than in the PD & SMI and PD only group (5%, 1.7% 
and 2%, respectively). This may indicate a lower validity of 
registered causes of death in the PD & SUD group.
We included all individuals with at least one PD diag-
nosis, which may result in a lower diagnostic specificity of 
PD. Subgroup analyses of the group of individuals with only 
one registered PD diagnosis showed a higher proportion of 
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4 years older at death), and a higher rate of natural causes 
of death, in particular alcohol related liver disease (ICD-10 
K70). To avoid selection bias through excluding a subgroup 
of patients with possible personality disturbances and lower 
rates of help-seeking behavior, we hence included patients 
with only one registered PD diagnosis, resulting in some-
what higher SMRs, but a similar pattern concerning mortal-
ity and comorbidity.
We chose to include individuals up to 79 years, which 
may have introduced uncertainty with respect to age related 
disorders, such as neurodegenerative diseases. However, 
very few studies address PD in older adults, and as under-
lined in a recent study by Penders and coworkers, there is 
an urgent need for studies investigating both age adequate 
assessment and treatment options as well as epidemiological 
aspects of PD in older age [67]. Additional analyses includ-
ing individuals up to 69 years only reduced the number of 
deaths with 8% and the point estimates for SMRs and haz-
ard ratios presented above (Table 3) were only marginally 
changed (results not shown). The relatively short follow-up 
represents a limitation that may lead to both under- and over-
estimation of SMR. There may also be an inflated prevalence 
of comorbidity in clinical samples (Berkson’s bias[25]), but 
underreporting of SMI and/or SUD in patients with PD is 
also possible. In addition, survivor bias could have led to 
underestimation of SMR in the comorbid groups; as the 
presence of two diagnoses may be associated with a more 
extensive follow-up period than one PD diagnosis only. The 
lack of control of unmeasured mortality risk factors is also 
an important limitation.
Conclusions
Our study shows extremely high mortality in patients 
with PDs and comorbid substance use disorders, or with 
a comorbid diagnosis of schizophrenia, bipolar disorder or 
severe depression, compared to the general population. PD 
patients with comorbid substance use disorders have a four-
fold increased risk compared to PD patients without such 
diagnoses, with young female patients being at highest risk. 
In patients with comorbid schizophrenia, bipolar disorder 
or severe depression, the risk is doubled. The mortality is 
particularly high in patients who were treated as inpatients, 
but the increased total mortality is also true for patients 
treated as outpatients only. The most profoundly increased 
mortality is due to unnatural causes of death, in particular 
poisoning and suicide. Although strongly associated with 
comorbidity, the mortality is also high in patients with per-
sonality disorders only, compared to the general population. 
Thus, the higher mortality in patients with personality dis-
orders described in many previous studies cannot fully be 
accounted for by comorbidity.
Implications
The results from our study implicate that special emphasis 
should be placed on patients with PD & SUD comorbid-
ity. These patients may be challenging to treat, as they 
often show complex symptomatology and reduced ability 
to develop stable relationships which may hamper treat-
ment alliance. Cooperative strategies should nevertheless 
be implemented for comorbid patients with PD & SUD 
treated in both mental health care and drug abuse treat-
ment facilities, to avoid “gaps” in treatment and follow-up. 
While preventing natural causes of death may be more 
relevant in patients with comorbid PD & SMI, targeted 
strategies to avoid premature mortality must be developed 
to prevent deaths due to unnatural causes in patients with 
comorbid PD & SUD.
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